More Ranbaxy woes

Share this article:

The FDA has put Ranbaxy Laboratories on notice.

Again.

Bloomberg reports that the US regulator says a recent inspection shows a Punjab, India, plant that makes 60% to 70% of the company's active ingredients is failing to make the grade.

The company agreed to shell out $500 million over fraud allegations in May, and Bloomberg notes that the US has already banned items from three Ranbaxy plants from entering the country.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.